Given that anti-PD-1 and anti-PD-L1 are promising to treat some types of solid cancers the CXCL9/CXCR3/PD-L1 axis may be new therapeutic targets for intervention of bladder cancers. This evidence concerns the gene CXCL9 and urinary bladder cancer.